Inhibrx Biosciences (INBX) Accounts Payables (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Accounts Payables data on file, last reported at $5.9 million in Q4 2025.

• Accounts Payables for Q4 2025 came in at $5.9 million, down 35.71% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.9 million (down 35.71% YoY), and the FY2025 annual result was $5.9 million, down 35.71% from the prior year.
• Accounts Payables retreated to $5.9 million in Q4 2025 per INBX's latest filing, from $6.8 million in the prior quarter.
• Over five years, Accounts Payables peaked at $13.0 million in Q2 2024 and troughed at $5.9 million in Q4 2025.
• A 3-year average of $9.4 million and a median of $9.1 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables dropped 15.6% in 2024, then tumbled 45.25% in 2025.
• A 3-year view of Accounts Payables shows it stood at $11.0 million in 2023, then retreated by 15.6% to $9.2 million in 2024, then sank by 35.71% to $5.9 million in 2025.
• Business Quant data shows INBX's Accounts Payables at $5.9 million in Q4 2025, $6.8 million in Q3 2025, and $8.3 million in Q2 2025.